Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1-loaded cord blood-derived dendritic cell vaccination after cord blood transplantation for pediatric and young adult AML
NL-OMON55718Phase 2Not yet recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2023
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of WT1 CBDC vaccine in acute myeloid leukemia (AML), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Dose-limiting toxicities and One-year WT1-positive AML relapse-free survival. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
WT1 CBDC vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON55718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55718.